STOCK TITAN

Eton (ETON) CBO sells 100,000 shares after exercising 87,794 options

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Eton Pharmaceuticals Chief Business Officer David Krempa exercised stock options and sold shares in several open-market trades. On May 22–27, 2026, he exercised options to acquire 87,794 shares of common stock at exercise prices of $1.37–$3.58 per share and sold 100,000 shares in open-market transactions at weighted average prices in the low-to-mid $30s, as detailed in the filing.

Following these transactions, he holds 25,249 shares of Eton common stock directly and retains 118,406 employee stock options, according to the reported post-transaction balances.

Positive

  • None.

Negative

  • None.
Insider Krempa David
Role Chief Business Officer
Sold 100,000 shs ($3.23M)
Type Security Shares Price Value
Exercise Employee Stock Option 12,476 $0.00 --
Exercise Employee Stock Option 7,203 $0.00 --
Exercise Common Stock 12,476 $1.37 $17K
Exercise Common Stock 7,203 $3.58 $26K
Sale Common Stock 19,679 $31.4739 $619K
Exercise Employee Stock Option 25,000 $0.00 --
Exercise Employee Stock Option 12,524 $0.00 --
Exercise Common Stock 25,000 $1.38 $35K
Exercise Common Stock 12,524 $1.37 $17K
Sale Common Stock 37,524 $31.4927 $1.18M
Exercise Employee Stock Option 30,591 $0.00 --
Exercise Common Stock 30,591 $3.58 $110K
Sale Common Stock 32,963 $33.2208 $1.10M
Sale Common Stock 9,315 $33.8802 $316K
Sale Common Stock 519 $35.00 $18K
Holdings After Transaction: Employee Stock Option — 0 shares (Direct, null); Common Stock — 37,725 shares (Direct, null)
Footnotes (1)
  1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price. The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price. The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested. The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price. The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments. The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price. The shares subject to option vested annually from the date of grant (8-7-2017) in four equal installments.
Shares sold 100,000 shares Total common shares sold across Form 4 period
Options exercised 87,794 shares Total common shares acquired via option exercises
Post-transaction common shares 25,249 shares Direct holdings after May 27, 2026 transactions
Remaining employee stock options 118,406 options Derivative holdings after latest option exercise
Sale price example $35.0000 per share One open-market sale on May 22, 2026
Weighted average sale price $33.2208 per share One tranche of common stock sold on May 22, 2026
Option exercise price $1.3700 per share Exercise price for certain options granted November 2017
Option exercise price $3.5800 per share Exercise price for certain options granted March 2020
open-market sale financial
"transaction_action: "open-market sale" for several common stock transactions"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Employee Stock Option financial
"security_title: "Employee Stock Option" for derivative transactions"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sales price financial
"footnote: "The price reported above reflects the weighted average sales price.""
vested in 48 equal monthly installments financial
"footnote: "The shares subject to the option vested in 48 equal monthly installments""
vested annually financial
"footnote: "The shares subject to the option vested annually from the date of grant""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krempa David

(Last)(First)(Middle)
C/O ETON PHARMACEUTICALS, INC.
21925 W. FIELD PARKWAY, SUITE 235

(Street)
DEERPARK ILLINOIS 60010-7208

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026M30,591A$3.5868,046D
Common Stock05/22/2026S32,963D$33.2208(1)(7)35,083D
Common Stock05/22/2026S9,315D$33.8802(1)(2)25,768D
Common Stock05/22/2026S519D$3525,249D
Common Stock05/26/2026M25,000A$1.3850,249D
Common Stock05/26/2026M12,524A$1.3762,773D
Common Stock05/26/2026S37,524D$31.4927(1)(3)25,249D
Common Stock05/27/2026M12,476A$1.3737,725D
Common Stock05/27/2026M7,203A$3.5844,928D
Common Stock05/27/2026S19,679D$31.4739(1)(5)25,249D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option$3.5805/22/2026M30,59103/12/2020(4)03/11/2030Common Stock30,591$0125,609D
Employee Stock Option$1.3805/26/2026M25,00008/07/2017(8)08/06/2027Common Stock25,000$00D
Employee Stock Option$1.3705/26/2026M12,52411/10/2017(6)11/09/2027Common Stock12,524$012,476D
Employee Stock Option$1.3705/27/2026M12,47611/10/2017(6)11/09/2027Common Stock12,476$00D
Employee Stock Option$3.5805/27/2026M7,20303/12/2020(4)03/11/2030Common Stock7,203$0118,406D
Explanation of Responses:
1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
2. The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price.
3. The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price.
4. The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested.
5. The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price.
6. The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
7. The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price.
8. The shares subject to option vested annually from the date of grant (8-7-2017) in four equal installments.
Remarks:
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.
/s/ Judith Matthews05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)